Navigation Links
GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Date:2/24/2010

RECORD provides the best, most reliable assessment of Avandia's cardiovascular safety. RECORD was initiated in 2001 and, in consultation with European regulators, was designed to compare cardiovascular outcomes of patients on Avandia added to metformin or sulfonylurea to those on metformin and sulfonylurea.  The study was sufficiently powered to confirm its primary hypothesis.  It showed that cardiovascular hospitalization or cardiovascular death (which includes heart attack, congestive heart failure, and stroke) was not statistically different between the two groups after an average of 5.5 years of therapy.

  • The report also fails to mention multiple other studies (APPROACH, VICTORY, STARR, VADT, ACCORD, BARI 2D) that all corroborate the ischemic cardiovascular safety of Avandia.  None of these studies show a statistically significant association between Avandia and heart attack or other ischemic cardiovascular events.

The absence in the Staff Report of any reference to the final results of the ADOPT, DREAM and RECORD studies, as well as other important studies on the ischemic cardiovascular safety of Avandia, leaves the record incomplete and does not s
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... MOUNT PROSPECT, Ill. , May 21, 2013 /PRNewswire-USNewswire/ ... Domain (gTLD) approval process, the National Association of Boards ... own and operate the .PHARMACY domain suffix has passed ... initial evaluation. NABP intends to launch the .PHARMACY gTLD ... new domain available to legitimate online pharmacies and related ...
(Date:5/21/2013)... Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: ... solution provider and operator of the largest network of ... parent of Chang,an Hospital, today reported its unaudited consolidated ... 2013 [1] . First Quarter 2013 Highlights ... revenues generated from the network business and hospital business, ...
(Date:5/21/2013)... , May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced that it has entered into ... and in-center products to DaVita, the kidney care division ... ) For the use of products ... , NxStage has executed a second amended and ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... 21, 2013 Arizona State University ... want to develop their ideas into solutions, products ... , The university is recruiting participants for AREA48 ... space” that provides early-stage entrepreneurs with opportunities to ... open to anyone, ASU is particularly seeking participation ...
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... guinea worm disease is almost eradicated from the planet earth. ... could be exterminated in a couple of years from now. ... ,Currently around 25,000 people in nine countries across the ... million people in twenty countries in the early 1980s. ...
... performance is reported to be the latest trend which is ... keen to learn and develop their skills to make sure ... interest of patients. ,More than 170 physician ... emergency care through the Physician Consortium for Performance Improvement organized ...
... cancers of the “triple negative” type are destructive and lethal, ... to a novel// study Published in the May 1, 2007 ... these tumors occur commonly among women who are African American ... the lower socioeconomic status (SES). The study also showed that ...
... children suffering ADHD are prone to alcohol addiction in ... suggesting that alcohol related problems could begin around the ... family stress appear to add to the risk of ... that children with attention deficit hyperactivity disorder (ADHD) are ...
... the incidence of chicken pox cases is on the rise. ... especially in the southern districts, are gearing up to tackle ... would be the first casualty if chicken pox is not ... cases have been already reported in a rather serious condition ...
... Going in for angioplasty? Pause for a moment. It has now ... arteries//. ,So much so, more than half a ... or premature angioplasty, suggests a new study. ,More important, ... heart patients, it says. ,Dr William Boden of ...
Cached Medicine News:Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 3
Alphabetically organized monographs on more than 1,000 generic and 3,000 trade name drugs....
... Drug Companion is a comprehensive, authoritative ... 5,500 entries, with overdose management, Canadian ... This "Mini-Suite" of drug references and ... the PEPID Suites (ED, PRIMARY CARE ...
... Pocket Drug Guide 2005 includes over 1,000 ... relating to their selection and administration. Organized ... drug includes key data featuring common uses ... implications and patient education information. A list ...
... A to Z Drug Facts ... detailed information on thousands of medications. ... contraindications, side effect, drug interactions, patient ... ideal drug reference for physicians, students, ...
Medicine Products: